Alzheimer's, Dementia & Mental Health
Brain Imaging Scan Finds Chemical Brain Change in Elderly at Risk of Alzheimer’s
Increasing evidence Alzheimer’s associated with changes in brain starting many years before symptoms show
Aug. 25, 2011 - A brain imaging scan of senior citizens in their 70s and 80s has identified biochemical changes in the
brains of normal people who might be at risk for Alzheimer's disease, according to research published in the August 24, 2011, online issue of
Neurology, the medical journal of the American Academy of Neurology.
The study of 311 elderly people with no cognitive problems, from the population-based Mayo Clinic Study of Aging, used an
advanced brain imaging technique called proton MR spectroscopy to see if they had abnormalities in several brain metabolites that may be
biomarkers for Alzheimer's disease.
They also had PET scans to assess the level of amyloid-beta deposits, or plaques, in the brain that are one of the first
signs of changes in the brain due to Alzheimer's disease. The participants were also given tests of memory, language and other skills.
"There is increasing evidence that Alzheimer disease is associated with changes in the brain that start many years before
symptoms develop," said Jonathan M. Schott, MD, of the Dementia Research Centre, University College London in England and a member of the
American Academy of Neurology, who wrote an editorial accompanying the study.
"If we could identify people in whom the disease process has started but symptoms have not yet developed, we would have a
potential window of opportunity for new treatments—as and when they become available—to prevent or delay the start of memory loss and
cognitive decline."
The study found that 33 percent of the participants had significantly high levels of amyloid-beta deposits in their
brains. Those with high levels of amyloid-beta deposits also tended to have high levels of the brain metabolites myoinositol/creatine and
choline/creatine.
People with high levels of choline/creatine were more likely to have lower scores on several of the cognitive tests,
regardless of the amount of amyloid-beta deposits in their brains.
"This relationship between amyloid-beta deposits and these metabolic changes in the brain are evidence that some of these
people may be in the earliest stages of the disease," said study author Kejal Kantarci, MD, MSc, of the Mayo Clinic in Rochester, Minn., and a
member of the American Academy of Neurology.
"More research is needed that follows people over a period of years to determine which of these individuals will actually
develop the disease and what the relationship is between the amyloid deposits and the metabolites." At the present time, MR spectroscopy
cannot be used for diagnosis.
The study was supported by the Paul Beeson Award in Aging, National Institutes of Health and the Robert H. and Clarice
Smith and Abigail Van Buren Alzheimer's Disease Research Program of the Mayo Foundation.
The American Academy of Neurology, an association of more than 24,000 neurologists and neuroscience professionals, says
it is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in
diagnosing, treating and managing disorders of the brain and nervous system such as epilepsy, dystonia, migraine, Huntington's disease, and
dementia.
For more information about the American Academy of Neurology, visit
http://www.aan.com.
VIDEO:
http://www.youtube.com/AANChannel
TEXT:
http://www.aan.com/press
TWEETS:
http://www.twitter.com/AANPublic
